Evidence Level
Quercetin has a deep evidence base as a dietary flavonoid with pharmacological activity. Its senolytic potential is the most exciting frontier — the quercetin + dasatinib combination pioneered by Mayo Clinic researchers (Kirkland & Tchkonia, 2020) has entered multiple clinical trials for aging-related diseases. Serban et al. (2016) conducted a comprehensive meta-analysis confirming blood pressure-lowering effects. The phytosome delivery system (Quercefit by Indena) has resolved quercetin's historically poor bioavailability, with Riva et al. (2019) demonstrating up to 20-fold improved plasma concentrations compared to standard quercetin. For immune function, Li et al. (2016) reviewed quercetin's mast cell stabilizing and cytokine-modulating effects.